Inovio Pharmaceuticals, Inc. (GBM.F)

Compare

1.8800

+0.0300

+(1.62%)

At close: 12:06:25 PM GMT+1

Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher

Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 19 days ago

INO
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study

PR Newswire 19 days ago

INO
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:

PR Newswire 21 days ago

INO
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

PR Newswire last month

INO
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings.

PR Newswire last month

INO
Top Midday Decliners

Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunreserti

PREMIUM
MT Newswires 2 months ago

RPTX

INO

CADL
INOVIO Announces Pricing of $30 Million Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 p

PR Newswire 2 months ago

INO
INOVIO Announces Proposed Public Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject

PR Newswire 2 months ago

INO
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate wa

PR Newswire 2 months ago

INO
INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

PR Newswire 3 months ago

INO
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals ( NASDAQ:INO ) Third Quarter 2024 Results Key Financial Results Net loss: US$25.2m (loss...

Simply Wall St. 3 months ago

INO
Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ...

Inovio Pharmaceuticals Inc (INO) advances towards BLA submission amid manufacturing challenges and competitive pressures.

GuruFocus.com 3 months ago

INO
Where are they now? 4 biotechs that soared then crashed during the pandemic

How Novavax and others have restructured and trudged forward after their COVID-era high.

Pharma Voice 3 months ago

CVAC

NVAX

INO
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript

INO earnings call for the period ending September 30, 2024.

Motley Fool 3 months ago

INO
Inovio: Q3 Earnings Snapshot

PLYMOUTH MEETING, Pa. AP) — Inovio Pharmaceuticals Inc. INO) on Thursday reported a loss of $25.2 million in its third quarter.

Associated Press Finance 3 months ago

INO
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.

PR Newswire 3 months ago

INO
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. In that prior trial, patients experienced a reduction in surgeries needed to control their RRP caused by HPV-6 and HPV-11. In

PR Newswire 3 months ago

INO
INOVIO to Present at Upcoming Scientific Conferences

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:

PR Newswire 3 months ago

INO
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

PR Newswire 3 months ago

INO
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.

PR Newswire 4 months ago

INO

Performance Overview

Return	GBM.F	S&P 500
YTD	+5.62%	-0.54%
1-Year	-78.16%	+13.87%
3-Year	-94.18%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inovio Pharmaceuticals, Inc. (GBM.F)

Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Top Midday Decliners

INOVIO Announces Pricing of $30 Million Public Offering

INOVIO Announces Proposed Public Offering

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

INOVIO Reports Inducement Grant Under Inducement Plan

Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ...

Where are they now? 4 biotechs that soared then crashed during the pandemic

Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript

Inovio: Q3 Earnings Snapshot

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

INOVIO to Present at Upcoming Scientific Conferences

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Performance Overview